156 related articles for article (PubMed ID: 35256158)
1. [Central nervous system disorders on lorlatinib: How to detect and manage in practice?].
Fallet V; Rouby P; Ahle G; Arrondeau J; Naltet C; Duflot-Boukobza A; De Crozals F; Lena H; Cortot A
Bull Cancer; 2022 Apr; 109(4):477-490. PubMed ID: 35256158
[TBL] [Abstract][Full Text] [Related]
2. Clinical Management of Adverse Events Associated with Lorlatinib.
Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
[TBL] [Abstract][Full Text] [Related]
3. A pragmatic guide for management of adverse events associated with lorlatinib.
Liu G; Mazieres J; Stratmann J; Ou SI; Mok T; Grizzard M; Goto Y; Felip E; Solomon BJ; Bauer TM
Lung Cancer; 2024 May; 191():107535. PubMed ID: 38554546
[TBL] [Abstract][Full Text] [Related]
4. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract][Full Text] [Related]
5. [Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib].
Zhou Q; Lu S; Li Y; Jia F; Li G; Hong Z; Lu Y; Fan Y; Zhou J; Liu Z; Li J; Wu YL; ;
Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):555-566. PubMed ID: 36002192
[TBL] [Abstract][Full Text] [Related]
6.
Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
[TBL] [Abstract][Full Text] [Related]
7. Lorlatinib as a treatment for ALK-positive lung cancer.
Baba K; Goto Y
Future Oncol; 2022 Aug; 18(24):2745-2766. PubMed ID: 35787143
[TBL] [Abstract][Full Text] [Related]
8. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
Sun S; Pithavala YK; Martini JF; Chen J
J Clin Pharmacol; 2022 Sep; 62(9):1170-1176. PubMed ID: 35373356
[TBL] [Abstract][Full Text] [Related]
10. Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases.
Murakami Y; Kawashima Y; Chiba S; Hara S; Yamazaki Y; Doman T; Saito S; Odaka T; Ogasawara T; Shimizu H; Sugisaka J; Aiba T; Toi Y; Yamanda S; Kimura Y; Sugawara S
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1981. PubMed ID: 38212894
[TBL] [Abstract][Full Text] [Related]
11. Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper.
Barata F; Aguiar C; Marques TR; Marques JB; Hespanhol V
Drug Saf; 2021 Aug; 44(8):825-834. PubMed ID: 34080177
[TBL] [Abstract][Full Text] [Related]
12. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological and clinical properties of lorlatinib in the treatment of
El Darsa H; Abdel-Rahman O; Sangha R
Expert Opin Pharmacother; 2020 Sep; 21(13):1547-1554. PubMed ID: 32511029
[TBL] [Abstract][Full Text] [Related]
14. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Naito T; Shiraishi H; Fujiwara Y
Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
[TBL] [Abstract][Full Text] [Related]
15. Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners.
Reed M; Rosales AS; Chioda MD; Parker L; Devgan G; Kettle J
Adv Ther; 2020 Jun; 37(6):3019-3030. PubMed ID: 32399810
[TBL] [Abstract][Full Text] [Related]
16. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
[TBL] [Abstract][Full Text] [Related]
17. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
18. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
Shiba-Ishii A; Johnson TW; Dagogo-Jack I; Mino-Kenudson M; Johnson TR; Wei P; Weinrich SL; McTigue MA; Walcott MA; Nguyen-Phuong L; Dionne K; Acker A; Kiedrowski LA; Do A; Peterson JL; Barth JL; Yeap BY; Gainor JF; Lin JJ; Yoda S; Hata AN
Nat Cancer; 2022 Jun; 3(6):710-722. PubMed ID: 35726063
[TBL] [Abstract][Full Text] [Related]
19. In-depth Analysis of Lorlatinib-related neurocognitive Adverse Events in Patients With Non-small-cell Lung Cancer.
Schoenmaekers J; Dijkstra J; van der Wekken A; Paats M; Broen M; Brandts L; Dingemans AM; Hendriks L
Clin Lung Cancer; 2024 Mar; 25(2):168-174.e1. PubMed ID: 38151408
[TBL] [Abstract][Full Text] [Related]
20. Lorlatinib induced proteinuria: A case report.
Lee CS; Wanchoo R; Seetharamu N
J Oncol Pharm Pract; 2021 Jun; 27(4):1037-1039. PubMed ID: 32996364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]